Niagen Bioscience, Inc. — Form 10-Q
Filed November 4, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 3/100
What the filing says
Robert N. Fried (CEO) and Ozan Pamir (CFO) signed standard SOX 302/906 certifications for Niagen Bioscience's Q3 2026 10-Q filed November 4, 2026. Both officers certified that the report contains no material misstatements, that financial statements fairly present the company's condition, and that disclosure controls and internal financial controls are in place and operating effectively. No material weaknesses, deficiencies, or fraud were disclosed.
Why this rating
Routine regulatory filing requirement. Standard SOX certifications contain no operational, financial, or strategic information; no changes to business disclosed.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.